The male patient presented in 2009 with a "3-year history of multiple interconnecting comedones in the axilla and inguinal regions, as well as scarring from previous lesions."
The researchers found that frequent HED was associated with decreased vertebral bone mineral density (BMD), even when controlling for variables most commonly associated with bone health such as lean body mass, physical activity, age at menarche, smoking, and oral contraception use.
According to the authors, this is the first study to identify medications most commonly reported for a specific adverse reaction using this database.
OsteoDetect is a computer-aided detection and diagnostic software that uses an algorithm to analyze 2-D wrist radiographs for signs of distal radius fracture.
The efficacy and safety of Prolia in the treatment of patients with glucocorticoid-induced osteoporosis was assessed in the 12-month primary analysis of a 2-year, randomized, multicenter, double-blind, parallel-group, active-controlled study (N=795).
In this multicenter, double-blind, placebo-controlled trial, patients (N=409) were randomized 1:1:1 to a postoperative regimen of IV tramadol 50mg, IV tramadol 25mg, or placebo administered over 15 minutes at hours 0, 2, 4, and once every 4 hours thereafter (up to 13 doses).
Using a privately-insured administrative database, researchers examined a total of 78,704 patients with autoimmune or inflammatory disease diagnoses between 2006 and 2015.
There was a significant correlation for anxiety levels with age, menopausal age, years since menopause, and depressive symptoms; multiple regression analysis predicted reduced BMD in the lumbar spine.
Researchers found that a non-immunosuppressant drug originally designed to treat osteoporosis (WAY-316606) targeted the same mechanism by antagonizing SFRP1, and after treating hair follicles with WAY-316606 for 6 days, the authors found enhanced human hair growth.
"Percutaneous vertebroplasty did not result in statistically significantly greater pain relief than a sham procedure during 12 months' follow-up among patients with acute osteoporotic vertebral compression fractures," the authors write.
Crysvita, a recombinant fully human monoclonal IgG1 antibody, works by blocking fibroblast growth factor 23 (FGF23), a hormone that causes phosphate urinary excretion and suppresses vitamin D production by the kidney.
The researchers found that intervention patients reported lower numeric rating scale pain scores on ambulation than the control group on postoperative day (POD) one (1.7 versus 5.0; P <.001).
Crysvita is an antibody that blocks fibroblast growth factor 23 (FGF23), a hormone that causes phosphate urinary excretion and suppresses active vitamin D production by the kidney.
The researchers found that 22.3% of patients had documented opioid use for more than 6 months before surgery, and 87.4% of these had continued long-term use postoperatively.
At the 43-month endpoint, a total of 60.7% (307/506) of the abaloparatide followed by alendronate group had ≥3% increase in bone mass at all 3 sites (P<0.0001) vs. 24% (121/505) of the placebo followed by alendronate group.
The researchers observed no significant difference between the groups in pain-related function over 12 months (overall P=0.58); the mean 12-month Brief Pain Inventory (BPI) interference was 3.4 and 3.3 for the opioid and non-opioid groups, respectively.
The researchers found that venous thromboembolism occurred in 0.64 and 0.7% of patients in the aspirin and rivaroxaban groups, respectively (difference, 0.06 percentage points; 95% confidence interval [CI], −0.55 to 0.66; P<0.001 for noninferiority and P=0.84 for superiority).
The researchers found that the MFS/ATR1a-null mice showed unabated aortic root enlargement and remained responsive to losartan, despite being hypotensive and resistant to AngII vasopressor effects.
Long-term ICS exposure at high doses was associated with a modest but significant increase in the risk of hip or upper extremity fractures.
In combination, state and facility characteristics explained 6.7% of the variation in hip fracture, and resident characteristics accounted for 7.6% of the variation.
"Our review of the current evidence has pointed to more questions than answers about the benefits and harms of screening children and teenagers with no symptoms of scoliosis," said USPSTF member Alex R. Kemper, MD, MPH.
Their results found that 22-24% of the hip injection group had new osteonecrosis vs. 5-9% of the hip control group and to 5% of the shoulder injection group.
Screening for osteoporosis with bone measurement testing should also occur in postmenopausal women <65 years who are at increased risk of osteoporosis as determined by a formal clinical risk assessment tool (B recommendation).
Noven announced that CombiPatch (estradiol/norethindrone acetate transdermal system) and Minivelle (estradiol transdermal system) are now readily available following a temporary product shortage.
ARCH (Active-contRolled FraCture Study in Postmenopausal Women with Osteoporosis at High Risk of Fracture) was a multicenter, international, randomized, double-blind, alendronate-controlled study (n=4,093) in postmenopausal women with osteoporosis at high risk for fracture based on previous fracture history.
The researchers found that 85.9% of patients reported using four or fewer opioid tablets, with 59.5% reporting that they used no opioid analgesics postoperatively.